PRE
ACHAT TOTAL: 18681 titres (~376598 USD)
- Insiders
- Yeung Danny Sheng Wu
- Total bought
- $376,598
- Total sold
- —
- Last activity
- 2026-08-24
- Last synced
-
2026-08-26 03:23:35
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-06
PRE presents a compelling near-term event-driven setup driven by a strong earnings catalyst (288% YoY revenue growth, raised guidance, and insider buying), but the weak fundamental health score (35) and persistent…
The first sentence of the analysis written for PRE on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 52.8% | 50.3% | 40.6% | 27.5% | 28.7% | |
| Ebit Margin | -38.9% | -187.8% | -256.1% | -1713.6% | -1727.6% | |
| Ebitda Margin | -34.8% | -168.4% | -220.3% | -1656.3% | -1668.9% | |
| Operating Profit Margin | -41.3% | -157.2% | -238.7% | -501.5% | -452.1% | |
| Pretax Profit Margin | -39.2% | -188.4% | -260.6% | -1715.4% | -1727.9% | |
| Continuous Operations Profit Margin | -39.2% | -162.7% | -259.4% | -1713.6% | -1748.4% | |
| Net Profit Margin | -40.8% | -151.2% | -288.5% | -1446.8% | -1388.4% | |
| Bottom Line Profit Margin | -40.8% | -151.2% | -288.5% | -1446.8% | -1388.4% | |
| Current Ratio | 3.014 | 2.357 | 2.372 | 4.228 | 1.820 | |
| Quick Ratio | 2.759 | 2.177 | 2.293 | 4.149 | 1.704 | |
| Solvency Ratio | -1.170 | -0.956 | -1.248 | -2.664 | -0.303 | |
| Cash Ratio | 1.161 | 1.430 | 1.158 | 2.564 | 0.601 | |
| Price To Earnings Ratio | -5.877 | -1.593 | -1.059 | -0.799 | -2.450 | |
| Price To Earnings Growth Ratio | 0.223 | 0.046 | 0.012 | 0.040 | -0.000 | |
| Forward Price To Earnings Growth Ratio | 0.223 | 0.046 | 0.012 | 0.040 | -0.000 | |
| Price To Earnings Diluted Ratio | -5.877 | -1.593 | -1.059 | -0.799 | -2.450 | |
| Price To Earnings Diluted Growth Ratio | 0.223 | 0.046 | 0.012 | 0.040 | -0.000 | |
| Price To Book Ratio | 1.268 | 0.432 | 0.322 | 0.642 | -1.064 | |
| Price To Sales Ratio | 2.396 | 2.406 | 3.057 | 11.553 | 34.013 | |
| Price To Free Cash Flow Ratio | -10.052 | -2.461 | -4.529 | 18.610 | 212.685 | |
| Price To Operating Cash Flow Ratio | -10.148 | -2.552 | -4.828 | 10.478 | 31.772 | |
| Debt To Assets Ratio | 0.011 | 0.027 | 0.009 | 0.021 | 3.311 | |
| Debt To Equity Ratio | 0.013 | 0.034 | 0.011 | 0.028 | -1.227 | |
| Debt To Capital Ratio | 0.012 | 0.033 | 0.011 | 0.027 | 5.411 | |
| Long Term Debt To Capital Ratio | 0.002 | 0.000 | 0.000 | 0.000 | 5.683 | |
| Financial Leverage Ratio | 1.166 | 1.253 | 1.232 | 1.317 | -0.371 | |
| Working Capital Turnover Ratio | 1.755 | 0.590 | 0.182 | 0.113 | 0.557 | |
| Operating Cash Flow Ratio | -0.788 | -0.790 | -0.349 | 0.254 | 0.228 | |
| Operating Cash Flow Sales Ratio | -0.236 | -0.943 | -0.633 | 1.103 | 1.071 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.010 | 1.037 | 1.066 | 0.563 | 0.149 | |
| Debt Service Coverage Ratio | -20.512 | -215.251 | -398.011 | -899.963 | -123.878 | |
| Interest Coverage Ratio | -158.212 | -237.163 | -433.778 | -272.818 | -1,341.776 | |
| Short Term Operating Cash Flow Coverage Ratio | -16.399 | 0.000 | 0.000 | 0.000 | 8.048 | |
| Operating Cash Flow Coverage Ratio | -9.896 | -5.002 | -5.810 | 2.184 | 0.027 | |
| Capital Expenditure Coverage Ratio | -104.861 | -27.112 | -15.096 | 2.288 | 1.176 | |
| Dividend Paid And Capex Coverage Ratio | -104.861 | -27.112 | -15.096 | 2.288 | 1.176 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.946 | -0.528 | -0.483 | -0.055 | -4.220 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 52.8% | ▲2.5% | ▲12.8% |
| Ebit Margin | -38.9% | ▲148.8% | ▲745.9% |
| Ebitda Margin | -34.8% | ▲133.6% | ▲714.9% |
| Operating Profit Margin | -41.3% | ▲116.0% | ▲236.9% |
| Pretax Profit Margin | -39.2% | ▲149.2% | ▲747.1% |
| Continuous Operations Profit Margin | -39.2% | ▲123.5% | ▲745.4% |
| Net Profit Margin | -40.8% | ▲110.4% | ▲622.3% |
| Bottom Line Profit Margin | -40.8% | ▲110.4% | ▲622.3% |
| Current Ratio | 3.014 | ▲0.657 | ▲0.256 |
| Quick Ratio | 2.759 | ▲0.582 | ▲0.142 |
| Solvency Ratio | -1.169 | ▼-0.213 | ▲0.099 |
| Cash Ratio | 1.161 | ▼-0.268 | ▼-0.221 |
| Price To Earnings Ratio | -5.877 | ▼-4.284 | ▼-3.521 |
| Price To Earnings Growth Ratio | 0.223 | ▲0.177 | ▲0.159 |
| Forward Price To Earnings Growth Ratio | 0.223 | ▲0.177 | ▲0.159 |
| Price To Earnings Diluted Ratio | -5.877 | ▼-4.284 | ▼-3.521 |
| Price To Earnings Diluted Growth Ratio | 0.223 | ▲0.177 | ▲0.159 |
| Price To Book Ratio | 1.268 | ▲0.835 | ▲0.948 |
| Price To Sales Ratio | 2.396 | ▼-0.011 | ▼-8.289 |
| Price To Free Cash Flow Ratio | -10.052 | ▼-7.591 | ▼-52.903 |
| Price To Operating Cash Flow Ratio | -10.148 | ▼-7.596 | ▼-15.092 |
| Debt To Assets Ratio | 0.011 | ▼-0.016 | ▼-0.665 |
| Debt To Equity Ratio | 0.013 | ▼-0.021 | ▲0.241 |
| Debt To Capital Ratio | 0.013 | ▼-0.020 | ▼-1.087 |
| Long Term Debt To Capital Ratio | 0.003 | ▲0.003 | ▼-1.135 |
| Financial Leverage Ratio | 1.166 | ▼-0.088 | ▲0.246 |
| Working Capital Turnover Ratio | 1.755 | ▲1.164 | ▲1.115 |
| Operating Cash Flow Ratio | -0.788 | ▲0.002 | ▼-0.499 |
| Operating Cash Flow Sales Ratio | -0.236 | ▲0.707 | ▼-0.308 |
| Free Cash Flow Operating Cash Flow Ratio | 1.010 | ▼-0.027 | ▲0.244 |
| Debt Service Coverage Ratio | -20.512 | ▲194.739 | ▲311.011 |
| Interest Coverage Ratio | -158.212 | ▲78.951 | ▲330.538 |
| Short Term Operating Cash Flow Coverage Ratio | -16.399 | ▼-16.399 | ▼-14.729 |
| Operating Cash Flow Coverage Ratio | -9.896 | ▼-4.894 | ▼-6.197 |
| Capital Expenditure Coverage Ratio | -104.861 | ▼-77.749 | ▼-76.140 |
| Dividend Paid And Capex Coverage Ratio | -104.861 | ▼-77.749 | ▼-76.140 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.946 | ▼-5.418 | ▼-3.700 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $221.3M | $73.7M | $66.5M | $152.1M | $426.3M | |
| Enterprise value | $191.4M | $27.2M | $23.1M | $12.1M | $882.7M | |
| EV / Sales | 2.07x | 0.89x | 1.06x | 0.92x | 70.43x | |
| EV / Op. cash flow | -8.78x | -0.94x | -1.68x | 0.83x | 65.79x | |
| EV / Free cash flow | -8.69x | -0.91x | -1.58x | 1.48x | 440.39x | |
| EV / EBITDA | -5.95x | -0.53x | -0.48x | -0.06x | -4.22x | |
| Net debt / EBITDA | 0.93x | 0.90x | 0.91x | 0.64x | -2.18x | |
| Current ratio | 3.01x | 2.36x | 2.37x | 4.23x | 1.82x | |
| Income quality | 0.41x | 0.58x | 0.21x | -0.08x | -0.08x | |
| Graham net-net | $3 | $2 | $3 | $30 | -$126 | |
| Tax burden | 104.1% | 80.2% | 110.7% | 84.3% | 80.4% | |
| Interest burden | 100.7% | 100.4% | 101.8% | 100.1% | 100.0% | |
| Working capital | $55.7M | $49.6M | $54.2M | $184.6M | $48.2M | |
| Invested capital | $102.2M | $106.3M | $102.5M | $246.3M | $89.0M | |
| Return on assets | -18.5% | -21.7% | -24.7% | -61.0% | -117.2% | |
| Operating ROA | -18.3% | -20.6% | -18.3% | -28.7% | -49.8% | |
| Return on tangible assets | -23.7% | -28.1% | -29.6% | -72.3% | -144.2% | |
| Return on equity | -21.6% | -27.2% | -30.4% | -80.3% | 43.4% | |
| Return on invested capital | -21.5% | -23.1% | -23.9% | -25.6% | -62.0% | |
| Return on capital employed | -21.7% | -27.2% | -24.2% | -25.9% | -63.1% | |
| Earnings yield | -17.0% | -62.8% | -94.4% | -125.2% | -40.8% | |
| Free cash flow yield | -9.9% | -40.6% | -22.1% | 5.4% | 0.5% | |
| Capex / Op. cash flow | -1.0% | -3.7% | -6.6% | 43.7% | 85.1% | |
| Capex / Depreciation | 5.5% | 18.0% | 11.7% | 84.1% | 155.3% | |
| Capex / Sales | 0.2% | 3.5% | 4.2% | 48.2% | 91.1% | |
| SG&A / Sales | 86.4% | 180.8% | 228.5% | 486.8% | 428.2% | |
| R&D / Sales | 5.6% | 35.7% | 53.6% | 45.5% | 51.0% | |
| Stock comp / Sales | 0.0% | 39.1% | 48.7% | 239.9% | 179.5% | |
| Intangibles / Total assets | 22.0% | 22.9% | 16.8% | 15.6% | 18.7% | |
| Days sales outstanding | 12d | 67d | 89d | 1178d | 1370d | |
| Days payables outstanding | 65d | 88d | 47d | 279d | 408d | |
| Operating cycle | 71d | 224d | 177d | 1352d | 1649d | |
| Cash conversion cycle | 6d | 136d | 130d | 1073d | 1242d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+200.4%EV / Sales ▲+133.1%EV / EBITDA ▼-1026.9%EV / Op. cash flow ▼-7.833Earnings yield ▲+0.458
Profitability
Return on equity ▲+0.056Return on assets ▲+0.032Return on invested capital ▲+0.016Return on capital employed ▲+0.055Operating ROA ▲+0.023Income quality ▼-0.166Tax burden ▲+0.239
Efficiency
Days sales outstanding ▼-55.030Days payables outstanding ▼-23.288Operating cycle ▼-153.413Cash conversion cycle ▼-130.125Capex / Sales ▼-0.033R&D / Sales ▼-0.301
Balance-sheet strength
Current ratio ▲+0.657Net debt / EBITDA ▲+0.028Working capital ▲+6120000.000Invested capital ▼-4171000.000Intangibles / Total assets ▼-0.010
Change over 5 years
Valuation
Market cap ▼-48.1%EV / Sales ▼-97.1%EV / EBITDA ▼-40.9%EV / Op. cash flow ▼-74.565Earnings yield ▲+0.238
Profitability
Return on equity ▼-0.650Return on assets ▲+0.986Return on invested capital ▲+0.404Return on capital employed ▲+0.414Operating ROA ▲+0.316Income quality ▲+0.491Tax burden ▲+0.238
Efficiency
Days sales outstanding ▼-1358.507Days payables outstanding ▼-343.229Operating cycle ▼-1578.567Cash conversion cycle ▼-1235.338Capex / Sales ▼-0.908R&D / Sales ▼-0.454
Balance-sheet strength
Current ratio ▲+1.194Net debt / EBITDA ▲+3.112Working capital ▲+7562202.000Invested capital ▲+13178663.000Intangibles / Total assets ▲+0.032
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-24 Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth Prenetics Global Limited has achieved explosive growth, reaching 140,000 subscriptions in 20 months, driven by its IM8 supplement and AI-powered marketing. One of the keys to this growth is its marketing mastery, using A/B and multivariate testing to quickly identify the most effective advertising messages. A unique deal with General Catalyst enables PRE to finance up to 70% of customer acquisition costs without equity dilution or debt, amplifying marketing leverage.
- 2026-08-22 Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript
- 2026-08-20 Prenetics'' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership — Lily is IM8''s first Global Ambassador from film and television, extending a roster built in elite sport into global entertainment and culture — Lily brings a following of more than 33 million across social platforms and an engagement rate of approximately 5.9%, several times the benchmark for accounts of comparable scale — Partnership lands as Prenetics raises FY 2026 revenue guidance to $220+ million; Initiates FY 2027 revenue guidance of $400+ million — Joins an equity-aligned roster of David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty and Inter Miami CF NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced a multi-year global partnership with two-time Golden Globe-nominated actress and producer Lily Collins, star and executive producer of Netflix''s Emily in Paris. Collins becomes a Global Ambassador of IM8 and a shareholder in Prenetics, demonstrating her long-term conviction in the brand and the Company.
- 2026-08-18 Prenetics Global Q2 Earnings Call Highlights Prenetics Global NASDAQ: PRE reported second-quarter revenue of $46.5 million, up 29% sequentially and about 3.9 times from a year earlier, as its IM8 supplement business continued to add subscribers and scale marketing spending. The company raised its full-year revenue outlook and said July marked its first month of positive consolidated adjusted free cash flow, including funding provided under its General Catalyst facility.
- 2026-08-18 Prenetics'' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond Prenetics'' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Co
- 2026-08-17 Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director 30+ years as one of Wall Street''s top-ranked equity research consumer analysts, including leadership of U.S. consumer research at UBS Caroline will also serve on the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. Prenetics will report its second quarter 2026 financial results tomorrow, Tuesday, August 18, 2026, and will host a live earnings webcast at 8:30 a.m.
- 2026-08-07 Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation
- 2026-07-23 TESLA AND ALPHABET SHARES SLUMP IN PRE-MARKET TRADING Alphabet shares pare back overnight as investors scrutinise its ever-increasing capex plans. Tesla is also down after missing on earnings while free cash flow turns negative.
- 2026-07-14 Prenetics'' IM8 Secures $1 Billion Growth Financing from General Catalyst''s Customer Value Fund (CVF) IM8 is the fastest-growing premium supplement brand ever recorded — over 50 million servings delivered to date, with approximately 200,000 servings currently delivered daily, and an order every 27 seconds Prenetics raises full-year 2026 IM8 revenue guidance to $210–220 million, up from $190–210 million IM8 expected to reach $300 million in annualized run-rate revenue by year-end 2026 IM8 expected to deliver $400 million or more in full-year 2027 revenue Every $1 invested in customer acquisition has returned $1.44 in gross profit, blended across all mature cohorts NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham, today announced the closing of $1 billion in growth financing from General Catalyst''s Customer Value Fund (“CVF”). Under the arrangement, General Catalyst''s Customer Value Fund will finance up to 70% of IM8''s marketing spend, with IM8 retaining full discretion over facility utilization.
- 2026-07-09 VINFAST LAUNCHES CERTIFIED PRE-OWNED PROGRAM, OFFERING PREMIUM ELECTRIC VEHICLES WITH INDUSTRY-LEADING 10-YEAR TRANSFERABLE WARRANTY IRVINE, Calif., July 9, 2026 /PRNewswire/ -- VinFast (Nasdaq: VFS) today announced the official launch of its Certified Pre-Owned (CPO) Program in the United States.